A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

Key facts

Sponsor

Merck Sharp & Dohme LLC

Principal Investigator

Medical Director

Merck Sharp & Dohme LLC

Intervention

Calderasib(drug)

Enrollment

600 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2031

Study locations (30)

• CBCC Global Research, Inc. ( Site 0123), Bakersfield, California, United States
• Beverly Hills Cancer Center ( Site 0116), Beverly Hills, California, United States
• Stamford Hospital ( Site 0136), Stamford, Connecticut, United States
• Mount Sinai Cancer Center ( Site 0137), Miami Beach, Florida, United States
• Orchard Healthcare Research Inc. ( Site 0115), Skokie, Illinois, United States
• Truman Medical Center ( Site 0126), Kansas City, Missouri, United States
• Cox Medical Center North ( Site 0133), Springfield, Missouri, United States
• St. Vincent Frontier Cancer Center-Research ( Site 0105), Billings, Montana, United States
• Atlantic Health System Morristown Medical Center ( Site 0121), Morristown, New Jersey, United States
• New York Oncology Hematology, P.C. ( Site 0132), Albany, New York, United States
• University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103), Cincinnati, Ohio, United States
• Kettering Health Main Campus-Kettering Health Cancer Center ( Site 0106), Kettering, Ohio, United States
• Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134), Lancaster, Pennsylvania, United States
• Oncology Consultants P.A. ( Site 0113), Houston, Texas, United States
• Circuit Clinical/SSM Health Dean Medical Group ( Site 0129), Madison, Wisconsin, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Small cell lung cancer

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT06694454
  Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
  National Cancer Institute (NCI)
• RECRUITINGNANCT07398599
  Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
  Second Affiliated Hospital of Nanchang University
• RECRUITINGPHASE1, PHASE2NCT07480213
  Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
  Beijing Biotech
• RECRUITINGPHASE1, PHASE2NCT07227597
  A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
  Merck Sharp & Dohme LLC
• RECRUITINGPHASE1NCT07348211
  First in Human Study of SIM0610 in Solid Tumors
  Jiangsu Simcere Pharmaceutical Co., Ltd.
• RECRUITINGNANCT07161310
  Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
  Goethe University
• RECRUITINGPHASE2NCT07304739
  Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE1, PHASE2NCT06956690
  A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
  Hummingbird Bioscience

See all trials for Small cell lung cancer →